---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-000083"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:20:19.954261+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics Appoints Yuan Xu, Ph.D., to Board of Directors

## Summary
- Board expanded from 8 to 9 directors; Dr. Xu appointed as Class II director effective Jan 4, 2022.
- Dr. Xu is former CEO of Legend Biotech and held senior roles at Merck, Gilead, Novartis.
- Her appointment comes as Xilio expects initial data readouts for XTX101 and XTX202 in 2022.
- Dr. Xu will receive standard non-employee director compensation and enter indemnification agreement.

## SEC filing metadata
- accession: 0001558370-22-000083
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/0001558370-22-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/xlo-20220104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-000083
- JSON: https://secwatch.observer/filing/0001558370-22-000083.json
- Plain text: https://secwatch.observer/filing/0001558370-22-000083.txt

## Key facts
- Executive change
  Yuan Xu was appointed as Director at Xilio Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective January 4, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Yuan Xu, Ph.D. to fill a newly created vacancy on the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022000083/0001558370-22-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.